


פרסומי הקבוצה הישראלית



SHORT COMMUNICATION

West Nile Virus Infection in Hospitalized Patients With Lymphoma and Multiple Myeloma—A Case Series Analysis

Yotam Bronstein¹  | Yael C Cohen^{1,2} | Shai Levi¹ | Ora Halutz³ | David Hagin^{2,4} | Irit Avivi^{1,2}

¹Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel | ²Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel | ³Clinical Microbiology Laboratory, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel | ⁴Allergy and Clinical Immunology Unit, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

LEUKEMIA & LYMPHOMA


<https://doi.org/10.1080/10428194.2025.2556175>





Taylor & Francis
Taylor & Francis Group

ORIGINAL ARTICLE

 OPEN ACCESS



First case report of talquetamab use in AL amyloidosis

Noa Gross Even-Zohar, Shlomzion Aumann, Adir Shaulov , Arnon Haran , Boaz Nachmias, Eyal Lebel , Roni Lehmann-Werman and Moshe E. Gatt

Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel



Contents lists available at [ScienceDirect](#)


The Ocular Surface

journal homepage: www.elsevier.com/locate/jtos



Interdisciplinary management of belantamab mafodotin-associated ocular toxicity in clinical practice



Mattan Arazi ^{a,b,c} , Aya Wattad ^{b,d}, Hila Magen ^{b,e}, Abraham Avigdor ^{b,e}, Nirit Agay ^f,
Yoav Berger ^{a,b}, Irina S. Barequet ^{a,b,*}

^a Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

^b Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

^c International Centre for Eye Health, London School of Hygiene and Tropical Medicine, London, UK

^d Ophthalmology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

^e Department of Haematology, Chaim Sheba Medical Center, Ramat-Gan, Israel

^f Biostatistics and Biomathematics Unit, Data and Analytics Center, Sheba Medical Center, Ramat Gan, Israel



REVIEW

 OPEN ACCESS


 Check for updates

Current experiences with teclistamab in patients with multiple myeloma and renal impairment

Meletios A Dimopoulos^{a,b}, Yael C Cohen^c, Aurore Perrot^d, Matthew J Pianko^e, Edward A Faber^f, Nelson Leung^g, María-Victoria Mateos^h and Ajay K Nookaⁱ

^aDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece; ^bDepartment of Medicine, Korea University, Seoul, South Korea; ^cTel-Aviv Sourasky (Ichilov) Medical Center, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; ^dUniversité de Toulouse, Centre Hospitalier Universitaire, Toulouse, France; ^eDepartment of Internal Medicine, University of Michigan Health, Ann Arbor, MI, USA; ^fAdult BMT & Cellular Therapy Program, University of Cincinnati, Cincinnati, OH, USA; ^gDepartment of Nephrology and Hypertension and Hematology, Mayo Clinic, Rochester, MN, USA; ^hHematology Department, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain; ⁱWinship Cancer Institute, Emory University, Atlanta, GA, USA

CyTOF profiling of bone marrow immune dynamics across myeloma stages

Dana Cholujo^a, Gabor Beke^b, Lubos Klucar^b, Lubos Drgona^c, Zuzana Valuskova^a, Merav Leiba^d,
Efsthios Kastritis^e, David M Dorfman^f, Kenneth C Anderson^{g,h}, and Jana Jakubikova ^{a,i}

^aDepartment of Tumor Immunology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia; ^bInstitute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia; ^cDepartment of Oncohematology, Comenius University and National Cancer Institute, Bratislava, Slovakia; ^dFaculty of Health Science, Assuta Ashdod University Hospital, Ben-Gurion University of the Negev, Ashdod, Israel; ^eDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; ^fDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA; ^gDana Farber Cancer Institute, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Boston, MA, USA; ^hDepartment of Medicine, Harvard Medical School, Boston, MA, USA; ⁱCentre for Advanced Material Application, Slovak Academy of Sciences, Bratislava, Slovakia


RESEARCH ARTICLES | JUNE 24 2025

Identification of Needs of Patients with Multiple Myeloma: A Questionnaire-Based Study in Israeli Patients

Subject Area:  [Hematology](#),  [Oncology](#)




[Ilana Levy Yurkovski](#) ; [Shira Ben-Dov](#); [Varda Shoam](#); [Micha Yuz](#); [Noa Lavi](#)

Acta Haematologica



Article

Deep-Learning-Based Prediction of t(11;14) in Multiple Myeloma H&E-Stained Samples

Nadav Kerner ^{1,*} , Dov Hershkovitz ^{1,2} , Svetlana Trestman ^{1,3}, Tamir Shragai ^{1,3}, Hila Lederman Nachmias ⁴, Yael C. Cohen ^{1,3}, Tomer Ziv-Baran ⁵  and Irit Avivi ^{1,3}

¹ Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel; dovh@tlvmc.gov.il (D.H.); svetlanat@tlvmc.gov.il (S.T.); tamirsh@tlvmc.gov.il (T.S.); yaelcoh@tlvmc.gov.il (Y.C.C.); iritavi@tlvmc.gov.il (I.A.)

² Pathology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel

³ Hematology Division, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel

⁴ Genetics Institute, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel; hilana@tlvmc.gov.il

⁵ School of Public Health, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel; zivtome@post.tau.ac.il

* Correspondence: nadavkerner@mail.tau.ac.il



American Society of Hematology
2021 L Street NW, Suite 900,
Washington, DC 20036
Phone: 202-776-0544 | Fax 202-776-0545
bloodadvances@hematology.org

Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumentAL-1

Tracking no: ADV-2025-016613R1

Carolina Schinke (University of Arkansas for Medical Sciences, United States) Paula Rodriguez-Otero (Cancer Center Clínica Universidad de Navarra, Spain) Niels W.C.J. van de Donk (Amsterdam UMC, Vrije Universiteit Amsterdam, Netherlands) Brea Lipe (University of Rochester Medical Center, United States) Noa Lavi (Rambam,) Leo Rasche (University Hospital Wuerzburg, Germany) Samir Parekh (Icahn School of Medicine at Mount Sinai, United States) Oliver Van Oekelen (Icahn School of Medicine at Mount Sinai, United States) Deeksha Vishwamitra (Johnson & Johnson, United States) Sheri Skerget (Johnson & Johnson, United States) Diana Cortes-Selva (Johnson & Johnson, United States) Raluca Verona (Johnson & Johnson, United States) Brandi Hilder (Johnson & Johnson, United States) Tara Masterson (Johnson & Johnson, United States) Michela Campagna (Johnson & Johnson, Spain) Sheetal Khedkar (Johnson & Johnson, United States) Thomas Renaud (Johnson & Johnson, United States) Jaszianne Tolbert (Johnson & Johnson, United States) Colleen Kane (Johnson & Johnson, United States) Kathleen Gray (Johnson & Johnson, United States) Ibrahim Saber (Johnson & Johnson, United States) Christoph Heuck (Johnson & Johnson, United States) Ajai Chari (Univeristy of California, San Francisco, United States)

יוזמות למחקרים משותפים של הקבוצה

Talquetamab for AL amyloidosis

- Treatment options for R/R AL amyloidosis progressing on ANDROMEDA are limited, especially for patients without t(11;14) translocation. Talquetamab, a CD3/GPRC5D bispecific antibody, showed significant efficacy for RRMM. Toxicity is notable for dysgeusia, weight loss and dermatologic disorders. Other immunotherapies, such as CAR-T and Teclistamab, have been successfully used for AL amyloidosis patients
- No data on TAL administration for AL amyloidosis
- AIM: to assess efficacy and safety of all Israeli AL amyloidosis treated with Talquetamab for AL amyloidosis

Real-World Comparison of Kyprolis-based Regimens vs. PVd in RRMM

- **Retrospective** multi-center study.
- Aim: To compare toxicity and efficacy of **KPd/KCd/Kd vs. PVd**.
- Inclusion: MM patients who had at least one previous line of therapy, receiving therapy with KPd, KCd, Kd or PVd.
- Exclusion: AL Amyloidosis.
- Main outcomes:
 - Hematological and non-hematological toxicities.
 - PFS
 - OS

Renana Robinson: 052-7018035, renana.robinson@gmail.com

The effect of steroid dose in frontline induction for AL amyloidosis in the novel agents' era

- **Aim:** To assess the effect of steroid dose in frontline induction for AL amyloidosis in the novel agents' era on key efficacy and toxicity outcomes
- **Hypothesis:** Steroids dose are commonly decreased in real-world induction for AL. This is associated with less toxicity and similar efficacy
- **Methods:** Retrospective multi-center study- Israeli multiple myeloma (MM) group
- **Included:** All AL amyloidosis patients treated in Israeli centers, receiving frontline therapy with bortezomib-based therapy (and/or dara-based).
- Data on steroid exposure, efficacy and toxicity is collected and analyzed

Israel Early access program - open 27/5/2025

Early access to innovation for patients, and early hands-on experience for EEs

Inclusion criteria

Diagnosis of MM and/or plasma cell dyscrasia and either:

• For combination with bortezomib/dexamethasone


BVd

- Previously treated with **at least 1 but no more than 2** prior lines of MM therapy and
- Must have documented disease progression during or after their most recent therapy

• For combination with pomalidomide/dexamethasone

BPd

- Previously treated with at **least 1 but no more than 2 prior lines** of MM therapy, including a lenalidomide-containing regimen (lenalidomide must have been administered for at least 2 consecutive cycles) and
 - Must have documented disease progression during or after their most recent therapy
- Note: Induction + ASCT + maintenance is 1 line of therapy. Patients treated with lenalidomide ≥ 10 mg daily for at least 2 consecutive cycles are eligible



מרכז רפואי	מספר מטופלים
איכילוב	28
ברמל	13
סורוקה	12
בילינסון	7
הלל יפה	5
הדסה	4
אסותא אשדוד	3
וולפסון	1
לניאדו	1
מאיר	1
רמב"ם	1
סה"כ מטופלים	76

76 patients